In recent times, practice in cardiac surgery has shifted towards using endoscopic techniques to harvest the saphenous vein from the leg for use as a bypass graft. A paper published in the New England Journal of Medicine (NEJM) in 2009 raised concerns over increased graft occlusion rates in veins harvested endoscopically. This NEJM paper has been criticized, but has nonetheless been influential in guiding practice. We have undertaken this meta-analysis to provide evidence on the clinical outcomes of endoscopic vein harvesting (EVH), so that clinicians can make an informed judgement about whether this technique, popular as it is with patients, should still be offered. We systematically reviewed the global literature and performed a meta-analysis of clinical outcomes after endoscopic and open vein harvesting. In all outcomes, endoscopic harvesting appears to be equal, if not superior, to open harvesting. The suspicion of higher rates of vein graft occlusion was not borne out by randomized studies. When considering evidence from only randomized studies, there is no statistical difference in vein graft stenosis or occlusion between open and endoscopically harvested veins. In conclusion, EVH reduces pain and leg wound complications. At a median follow-up of 2.6 years, we found no significant difference in mortality, myocardial infarction, repeat revascularization, angina recurrence, vein graft stenosis or occlusion. Therefore, the authors support the ongoing use of endoscopic harvesting techniques.
INTRODUCTION
Coronary artery bypass grafting (CABG) is one of the most effective and frequently performed operations in the world today. An estimated 23 000 cases are performed each year in the UK [1] and 800 000 per year worldwide [2] . This operation requires an autologous conduit; the most frequently used (and arguably the best) are the internal mammary artery [3] and saphenous vein, retrieved from the leg at the time of heart surgery. Long incisions in the leg for open vein harvesting (OVH) are associated with infection and delayed walking, which lead to longer hospital stays [4] . It was proposed that smaller incisions would minimize these problems, driving the development of endoscopic vein harvesting (EVH), which is now a frequently employed technique. However, Lopes et al. [5] published in the NEJM in 2009 that EVH was associated with a near-doubling of mortality 18 months after CABG when compared with OVH. Concerns over mortality have been echoed by others [6] . For this reason, we have undertaken to perform this meta-analysis so as to more clearly inform our best practice. study with the longest follow-up. Each study was evaluated by the Downs and Black [7] quality assessment method. 
Study outcomes

Statistical analysis
For each outcome, study results comparing patients undergoing EVH and those undergoing OVH were statistically combined in a meta-analysis to generate an overall pooled summary statistic with a 95% confidence interval. For continuous variables, studies were combined according to their un-standardized mean differences (SMD). For categorical variables, studies were combined using log-rate ratios (SRRate) if the outcome was examined over a period of observation; otherwise, log-relative risks (SRRisk) were used. A random-effects meta-analysis method with the DerSimonian-Laird estimator was used in order to take into account heterogeneity between studies. For the log-relative risk and log-rate ratio outcomes, zero-total event studies were removed from the meta-analysis as recommended by Whitehead and Whitehead [8] . Where zero events were reported, a continuity correction was applied to the relevant contingency tables used in the meta-analysis. The Cochran Q and I 2 statistics were used to test for significant heterogeneity between studies. To assess the presence of publication bias, funnel plots were produced and a regression test for funnel plot asymmetry was performed evaluating the relationship between effect size and standard error (mixed-effects meta-regression model). A sensitivity analysis was then performed on all studies, whereby the same meta-analysis method was performed as above, except that only high-quality randomized controlled trials were included in the meta-analysis.
The influence of devices on clinical outcomes was assessed using a random-effects meta-regression to determine if the devices moderate the overall effect size (EVH relative to OVH) for each outcome. For analysis, studies were categorized into three broad categories: VasoView, Ethicon EVH kit 2 and other devices. Where meta-regression was not possible due to low numbers of studies in each device group, a sensitivity analysis was used to evaluate the effect of including studies using a specific device only (e.g. VasoView system). For some cases, not even a sensitivity analysis was appropriate due to low numbers. Statistical analyses were performed using the R software for Windows (Version 2.14.0; [9] ).
RESULTS
We identified 44 studies eligible for inclusion, 19 randomized and 25 non-randomized (see Fig. 1 and Table 2 ). All studies achieved a quality assessment score of ≥13. Table 2 shows the  study characteristics and Table 3 shows the pooled demographic data. The results of our 11 outcomes are summarized in Table 4 . The abridged results in each domain of interest are described below and shown in Figs 2 and 3. Unless otherwise stated, tests of heterogeneity and regression tests of funnel plot asymmetry were non-significant for each outcome. Early outcomes are displayed in forest plots of randomized trials only (Fig. 2 ). In contrast, and due to lack of randomized trials, the mid-term outcomes are displayed in forest plots of all trials (Fig. 3) . Comprehensive results including all forest plots, funnel plots and tests of asymmetry are available on request.
Postoperative pain
Twelve studies reported on postoperative pain in a total of 663 patients. Six studies were prospectively randomized (PR), 3 were prospective but non-randomized (PNR) and 3 were retrospective, non-randomized studies (RNR). Analysis of all 12 studies indicated lower pain scores in the EVH group (SMD −1.48, 95% CI −2.38 to −0.59, P = 0.001) and this was confirmed after excluding non-randomized studies (SMD −1.75, 95% CI −3.17 to −0.32, P = 0.02). Significant heterogeneity was observed in both meta-analyses (I 2 statistic 98% for all studies). This was partly due to differences in the device system used across studies. The effect size of postoperative pain was found to be significantly lower for studies using the Ethicon system (P = 0.0006) and those using a system other than Ethicon or VasoView (P = 0.007), compared with studies using VasoView. Indeed, after excluding all studies not using the VasoView system, the overall effect size for postoperative pain became non-significant (P = 0.052). 
Wound infection
Thirty-one studies (15 PR, 7 PNR and 9 RNR) reported on wound infection in a total of 11 352 patients. Analysis of all 31 studies indicated less wound infection in the EVH groups (SRRisk 0.31, 95% CI 0.23-0.42, P < 0.0001), and this was confirmed after excluding non-randomized data (SRRisk 0.26, 95% CI 0.15-0.44, P < 0.0001). Significant heterogeneity was observed in both meta-analyses (I 2 statistic 43% for all studies). The corresponding funnel plot showed no clear evidence of publication bias. However, the regression test was significant in both meta-analyses (see Table 4 ). Hence, these results should be interpreted with caution since the regression test suggests the presence of publication bias. The device was found to have no significant influence on effect size: Ethicon compared with VasoView (P = 0.50); other devices compared with VasoView (P = 0.44); other devices compared with Ethicon (P = 0.89).
All-cause wound complications
Here, we analyzed a composite of all wound complications described in the 44 papers (see Table 1 ), thereby allowing for the variety and overlap in the definitions employed by the authors. Thirty-eight studies (17 PR, 11 PNR and 10 RNR) reported on wound complications in a total of 261 194 patients. Analysis of all 38 studies indicated a lower incidence of wound complications in the EVH groups. However, publication bias was evident in the funnel plot and the regression test produced a very strongly significant P-value (P = 0.0005), even when nonrandomized data were excluded (P = 0.006). There was also a significant degree of heterogeneity (I 2 statistic 85% for all studies) so no summary effect size estimate is presented. In summary, these data are unreliable due to observed heterogeneity and probable publication bias.
Postoperative MI (within 30 days of CABG)
Twelve studies (3 PR, 4 PNR and 5 RNR) reported on postoperative myocardial infarction (MI) in a total of 1872 patients. Analysis of all 12 studies did not indicate a difference in postoperative MI between the two groups (SRRisk 0.87, 95% CI 0.68-1.11, P = 0.26). The results were similar after excluding the nonrandomized data (SRRisk 1.34, 95% CI 0.30-5.89, P = 0.70). No significant difference was found between the EVH and OVH groups in postoperative MI incidence. The device was found to have no significant influence on the overall summary effect size: Ethicon compared with VasoView (P = 0.71); other devices compared with VasoView (P = 0.77); other devices compared with Ethicon (P = 0.83).
30-day mortality
Sixteen studies (7 PR, 4 PNR and 5 RNR) reported on 30-day mortality in a total of 14 190 patients. The SRRisk was 0.71, 95% CI 0.56-0.90, P = 0.005, indicating a lower incidence of 30-day mortality in the EVH group. Exclusion of the non-randomized data resulted in SRRisk 0.75, 95% CI 0.27-2.11, P = 0.58. In summary, although there was a trend towards 30-day survival benefit in EVH over OVH groups, there was no clear evidence for this when considering randomized controlled trials only. The 
Vein graft stenosis
Three studies (2 PR and 1 RNR) considered vein graft stenosis, reporting on a total of 3229 patients. In the two prospective studies, angiography was performed at 3, and 6 months. In the RNR study, angiograms were reviewed at a median 12.6 months after CABG. The SRRatio was 1.19, 95% CI 1.05-1.34, P = 0.005. However, neither of the randomized studies showed any significant difference between the groups. In conclusion, the evidence for increased rates of vein graft stenosis after EVH is very weak. More studies are needed to investigate this further. It was not possible to assess the influence of the devices on overall effect size due to the low numbers of studies (only two studies had non-missing information on device), and the fact that both remaining devices used the VasoView system.
Vein graft occlusion
Four studies (2 PR, 1 PNR and 1 RNR) reported on vein graft occlusion in a total of 4700 patients. Analysing the data from all four studies, the SRRatio was 1.39 (95% CI 1.11-1.75, P = 0.004), suggesting a higher rate of vein graft occlusion in the EVH group. However, when considering only the two randomized control trials the difference in vein graft occlusion between the groups was non-significant (see Fig. 4) . It was not possible to assess the influence of devices on overall effect size due to low numbers of studies (only two studies had non-missing information on devices), and the fact that both remaining devices used the VasoView system. In conclusion, the evidence for increased rates of vein graft occlusion after EVH is very weak.
Angina recurrence
This was assessed in four studies (2 PR, 1 PNR and 1 RNR) reporting on a total of 6401 patients. In the 2 PR studies, the follow-up was 6 months. In the PNR study, the median follow-up was 2.6 years. In the remaining study, median follow-up was 17 months after EVH and 37 months after OVH. The rate of angina recurrence was not significantly different between groups (SRRatio 1.06, 95% CI 0.49-2.25, P = 0.81), even after removing the non-randomized studies (SRRatio of 0.79, 95% CI 0.15-4.18, P = 0.78). Also, after a sensitivity analysis removing the study reporting only a hazard ratio (Ouzounian) our conclusions were unchanged. Our results were also unchanged after a sensitivity analysis including the VasoView studies only (P = 0.89). In summary, there was insufficient evidence to show that the rate of angina recurrence is any different between the EVH and OVH groups.
Repeat revascularization
This was assessed in seven studies (1 PR, 2 PNR and 4 RNR), reporting on a total of 21 743 patients. One of the RNR studies did not publish the duration of follow-up. In the other seven studies, the median follow-up was 2.3 years. The SRRatio was 1.16, 95% CI 0.99-1.36, P = 0.06, indicating insufficient evidence of any difference in the repeat revascularization rate. The one randomized study yielded an SR Ratio of 0.34, 95% CI 0.01-8.25 after continuity correction, indicating no significant difference between groups. Our conclusions were unchanged after performing a sensitivity analysis excluding studies reporting hazard ratios (SR Ratio 1.19; 95% CI 0.96-1.46; P = 0.12). It was not possible to assess the influence of the devices on overall effect size due to all studies using the VasoView system. Three studies had missing data on the devices. In summary, there is insufficient evidence of any difference in the rate of repeat revascularization between groups.
Mid-term myocardial infarction
This was considered in six studies (1 PR, 2 PNR and 3 RNR) reporting on a total of 12 740 patients over a mean followup of 26.5 months. There was insufficient evidence of a difference between groups in the risk of mid-term MI 
Mid-term mortality
Ten studies (1 PR, 2 PNR and 7 RNR) considered mid-term mortality reporting on a total of 252 915 patients over a median follow-up of 22.5 months. The SR Ratio was 0.90, 95% CI 0.79-1.03, P = 0.12, which indicates insufficient evidence for a difference in mid-term mortality. There was substantial heterogeneity between the studies (I²-statistic 47%). Our conclusions remained unchanged after sensitivity analysis excluding studies with hazard ratios (SRRatio 0.90; 95% CI 0.68-1·19; P = 0.45). Also, the only randomized study reported a rate ratio of 3.00 with 95% CI 0.13-71.52; P = 0.50. Therefore, there is insufficient evidence of a difference in mid-term mortality between the EVH and OVH groups. It was not possible to assess the influence of the devices on overall effect size due to all devices using the VasoView system.
DISCUSSION
Endoscopic harvesting of the saphenous vein is an increasingly popular technique, used in the majority of CABG operations in North America [10] . In the UK, the technique has not been met with quite such enthusiasm. National Institute for Health and . Previous meta-analyses have not fully addressed these concerns. In this meta-analysis reviewing data from 267 525 patients, we have shown that EVH benefits patients in the short-term by reducing the rate of wound infection and postoperative pain after vein harvesting (albeit that this is dependent on the harvesting system used). Consequently, EVH has become very popular with patients who report greater satisfaction with the cosmetic result and lack of pain [11] [12] [13] [14] . Crucially, we have demonstrated that over and above this early benefit, there is insufficient evidence of mid-term clinical disadvantage at 2 years. Previously, concern had been raised regarding the angiographical disadvantage in terms of vein graft occlusion at the 12-month follow-up. This was evident in the forest plot including all study types (Fig. 3) . However, when considering randomized studies alone (Fig. 4) , there was insufficient evidence of a difference in vein graft occlusion. Observational studies are more susceptible to bias, which may explain this discrepancy. Regarding other important clinical outcomes (angina recurrence, repeat revascularization, MI and mortality), RCTs have shown only benefits or no significant difference between EVH and OVH groups at a mean follow-up of 2 years. Studies have also shown that EVH is probably more cost-effective than OVH because of reduced hospital stay and wound morbidity [15] . Therefore in many centres across the world, EVH has been adopted as routine practice. However, the support for EVH among surgeons faltered after the publication of the PREVENT-IV sub-analysis [5] , which cited an increased risk of vein graft occlusion at a median of 12.6 months (46.7% EVH vs 38% OVH), and a higher composite rate of death, MI or revascularization (20.2 vs 17.4%; adjusted hazard ratio 1.22; 95% CI 1.01-1.47; P = 0.04). These concerns were echoed in a secondary analysis of data from the ROOBY trial that compared off-and on-pump CABG [16] . Neither of these trials were designed or powered to examine differences due to the vein-harvesting technique. In our meta-analysis, we found the evidence of increased vein graft occlusion to be weak, derived as it is from non-randomized studies. We believe we have shown that EVH is favourable in terms of short-term outcomes. It reduces pain and wound infections significantly. It also reduces hospital stay according to Athanasiou et al.'s meta-analysis [17] , which showed that EVH patients stay in hospital 1 day less. Accepting this to be true, routine EVH would release sufficient resources in the UK centres to perform at least another 2000 CABG procedures each year. However, prior to advocating EVH as a standard approach, we must consider its impact on long-term quality and quantity of life. Recent studies have raised concerns about the endothelial function of vein harvested by EVH [18, 19] . Endothelial function is a determinant of long-term graft patency, which in turn influences long-term survival after CABG. It is well recognized that late vein graft failure due to progression of vasculopathy becomes pronounced at 7-10 years after the original CABG operation. Therefore, we will not know how EVH compares with OVH in terms of long-term patency until studies are performed with at least a decade of follow-up. With these reservations in mind, we are reassured that our meta-analysis has shown that important outcomes (MI, revascularization, death) are similar for EVH and OVH at 2 years. Encouraged by these results, we can say that although the case for OVH is not yet closed, EVH does appear to be a safe technique in the mid-term, which reduces wound complications and pain without compromising graft patency at 2 years.
LIMITATIONS
There are very few long-term prospective studies examining clinical and angiographic outcomes after EVH and OVH. It is therefore difficult to make a clear statement about the long-term safety and efficacy of EVH as an adjunct to coronary revascularization. A randomized control trial of EVH vs OVH (the ESOS trial) was registered in 2011. It is hoped that this trial will provide level 1A evidence as to the relative benefits of EVH. However, this trial is planned to report its findings after only 2 years. There is a clear necessity for a randomized controlled trial providing the follow-up beyond the vein graft failure peak at 7-10 years after surgery to enable surgeons to make evidencebased decisions when choosing the conduit and harvesting technique. This is even more important if we consider the potential resurgence in the use of arterial grafts, based on recent evidence from ARTS, RAPS and other similar studies. The radial artery as a second conduit has similar benefits to EVH in terms of improved postoperative mobility and cosmesis. The debate over conduit choice and long-term graft patency is therefore very much alive and must be appropriately informed by high-quality largevolume randomized trials. CONCLUSION EVH appears to be a safe technique for harvesting veins for CABG surgery. In comparison with OVH, there is a demonstrated benefit in the categories of postoperative pain and wound infection. Additionally, patient satisfaction and overall wound complications have been reported to be superior with EVH. No significant difference could be detected in the outcomes of postoperative MI, mid-term MI, mid-term mortality, recurrence of angina and repeat revascularization. This meta-analysis suggests that EVH is no worse than OVH and appears to be associated with lower levels of postoperative pain, particularly in studies using the VasoView system. In contrast to Lopes et al., no compromised long-term effects could be detected. However, further studies need to be conducted, focussing on vein graft occlusion and stenosis, since the body of evidence is weighted towards short-term non-randomized studies and is therefore insufficient to forecast long-term outcomes. In accordance with other authors, however, we consider EVH to be a safe and effective technique at a viewpoint of 2.6 years, which can be safely adopted as a standard of care.
